Clinical Trial Update: Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI） [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on Argatroban plus rt-PA for posterior circulation infarction has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posterior Circulation Infarction
• Stroke

Drugs mentioned

• Argatroban (argatroban)
• rt-PA (tissue plasminogen activator)

Snippet

Sponsor: Hui-Sheng Chen | Conditions: Argatroban, Rt-PA | Phase 4 | Status: TERMINATED